11/28
04:33 am
nbix
Neurocrine Biosciences (NBIX): Revisiting Valuation Following Decade-Long VMAT2 Review Publication [Yahoo! Finance]
Low
Report
Neurocrine Biosciences (NBIX): Revisiting Valuation Following Decade-Long VMAT2 Review Publication [Yahoo! Finance]
11/20
08:30 am
nbix
Neurocrine Biosciences Announces Publication of Landmark Narrative Review on FDA-Approved VMAT2 Inhibitors Demonstrating Unique Profile of INGREZZA® (valbenazine) Capsules
Low
Report
Neurocrine Biosciences Announces Publication of Landmark Narrative Review on FDA-Approved VMAT2 Inhibitors Demonstrating Unique Profile of INGREZZA® (valbenazine) Capsules
11/18
04:57 pm
nbix
Neurona Therapeutics Appoints Dr. Eduardo Dunayevich as Chief Medical Officer [Yahoo! Finance]
Low
Report
Neurona Therapeutics Appoints Dr. Eduardo Dunayevich as Chief Medical Officer [Yahoo! Finance]
11/12
07:10 pm
nbix
Assessing Neurocrine Biosciences After Stock Rises 7.8% and Partnership Expansion News [Yahoo! Finance]
Low
Report
Assessing Neurocrine Biosciences After Stock Rises 7.8% and Partnership Expansion News [Yahoo! Finance]
11/11
04:01 pm
nbix
Neurocrine Biosciences to Present at Upcoming Investor Conferences
Low
Report
Neurocrine Biosciences to Present at Upcoming Investor Conferences
11/11
08:09 am
nbix
Neurocrine Biosciences (NASDAQ:NBIX) had its price target lowered by analysts at Morgan Stanley from $178.00 to $173.00. They now have an "overweight" rating on the stock.
Low
Report
Neurocrine Biosciences (NASDAQ:NBIX) had its price target lowered by analysts at Morgan Stanley from $178.00 to $173.00. They now have an "overweight" rating on the stock.
11/10
07:08 pm
nbix
Neurocrine chalks up a depression drug failure [Yahoo! Finance]
Low
Report
Neurocrine chalks up a depression drug failure [Yahoo! Finance]
11/10
04:09 pm
nbix
Neurocrine Biosciences Provides Update on Phase 2 Study of NBI-1070770 in Adults with Major Depressive Disorder [Yahoo! Finance]
Medium
Report
Neurocrine Biosciences Provides Update on Phase 2 Study of NBI-1070770 in Adults with Major Depressive Disorder [Yahoo! Finance]
11/10
04:05 pm
nbix
Neurocrine Biosciences Provides Update on Phase 2 Study of NBI-1070770 in Adults with Major Depressive Disorder
Low
Report
Neurocrine Biosciences Provides Update on Phase 2 Study of NBI-1070770 in Adults with Major Depressive Disorder
11/3
10:42 am
nbix
Neurocrine Biosciences (NASDAQ:NBIX) had its price target raised by analysts at JPMorgan Chase & Co. from $171.00 to $179.00. They now have an "overweight" rating on the stock.
Low
Report
Neurocrine Biosciences (NASDAQ:NBIX) had its price target raised by analysts at JPMorgan Chase & Co. from $171.00 to $179.00. They now have an "overweight" rating on the stock.
10/30
09:04 am
nbix
Neurocrine Biosciences (NASDAQ:NBIX) had its "buy" rating reaffirmed by analysts at Truist Financial Corporation. They now have a $172.00 price target on the stock, up previously from $165.00.
Low
Report
Neurocrine Biosciences (NASDAQ:NBIX) had its "buy" rating reaffirmed by analysts at Truist Financial Corporation. They now have a $172.00 price target on the stock, up previously from $165.00.
10/29
04:48 pm
nbix
Neurocrine Biosciences (NASDAQ:NBIX) had its price target raised by analysts at Canaccord Genuity Group Inc. from $160.00 to $164.00. They now have a "buy" rating on the stock.
Low
Report
Neurocrine Biosciences (NASDAQ:NBIX) had its price target raised by analysts at Canaccord Genuity Group Inc. from $160.00 to $164.00. They now have a "buy" rating on the stock.
10/29
02:51 pm
nbix
Neurocrine Biosciences (NASDAQ:NBIX) had its price target raised by analysts at Citigroup Inc. from $175.00 to $203.00. They now have a "buy" rating on the stock.
Low
Report
Neurocrine Biosciences (NASDAQ:NBIX) had its price target raised by analysts at Citigroup Inc. from $175.00 to $203.00. They now have a "buy" rating on the stock.
10/29
01:47 pm
nbix
Neurocrine Biosciences (NASDAQ:NBIX) had its price target raised by analysts at Royal Bank Of Canada from $156.00 to $160.00. They now have an "outperform" rating on the stock.
Low
Report
Neurocrine Biosciences (NASDAQ:NBIX) had its price target raised by analysts at Royal Bank Of Canada from $156.00 to $160.00. They now have an "outperform" rating on the stock.
10/29
01:47 pm
nbix
Neurocrine Biosciences (NASDAQ:NBIX) had its price target raised by analysts at Stifel Nicolaus from $174.00 to $183.00. They now have a "buy" rating on the stock.
Low
Report
Neurocrine Biosciences (NASDAQ:NBIX) had its price target raised by analysts at Stifel Nicolaus from $174.00 to $183.00. They now have a "buy" rating on the stock.
10/29
09:36 am
nbix
Neurocrine Biosciences (NASDAQ:NBIX) had its price target raised by analysts at Piper Sandler from $175.00 to $179.00. They now have an "overweight" rating on the stock.
Low
Report
Neurocrine Biosciences (NASDAQ:NBIX) had its price target raised by analysts at Piper Sandler from $175.00 to $179.00. They now have an "overweight" rating on the stock.
10/29
08:08 am
nbix
Neurocrine Biosciences (NASDAQ:NBIX) had its price target raised by analysts at Needham & Company LLC from $170.00 to $184.00. They now have a "buy" rating on the stock.
Medium
Report
Neurocrine Biosciences (NASDAQ:NBIX) had its price target raised by analysts at Needham & Company LLC from $170.00 to $184.00. They now have a "buy" rating on the stock.
10/28
04:01 pm
nbix
Neurocrine Biosciences Reports Third Quarter 2025 Financial Results
Medium
Report
Neurocrine Biosciences Reports Third Quarter 2025 Financial Results
10/25
08:33 am
nbix
Examining Neurocrine Biosciences Valuation After 24% Stock Surge and Pipeline Progress in 2025 [Yahoo! Finance]
Medium
Report
Examining Neurocrine Biosciences Valuation After 24% Stock Surge and Pipeline Progress in 2025 [Yahoo! Finance]
10/21
08:03 am
nbix
Neurocrine Biosciences (NASDAQ:NBIX) is now covered by analysts at Citigroup Inc.. They set a "buy" rating and a $175.00 price target on the stock.
Low
Report
Neurocrine Biosciences (NASDAQ:NBIX) is now covered by analysts at Citigroup Inc.. They set a "buy" rating and a $175.00 price target on the stock.
10/20
01:29 pm
nbix
Neurocrine Biosciences (NASDAQ:NBIX) had its price target raised by analysts at Morgan Stanley from $163.00 to $168.00. They now have an "overweight" rating on the stock.
Low
Report
Neurocrine Biosciences (NASDAQ:NBIX) had its price target raised by analysts at Morgan Stanley from $163.00 to $168.00. They now have an "overweight" rating on the stock.
10/18
04:50 am
nbix
Neurocrine Biosciences: Buy Rated As Q3 2025 Earnings Catalyst Approaches [Seeking Alpha]
Low
Report
Neurocrine Biosciences: Buy Rated As Q3 2025 Earnings Catalyst Approaches [Seeking Alpha]
10/17
08:30 am
nbix
Neurocrine Biosciences Presents New KINECT® 4 Post-Hoc Analysis Demonstrating Rapid and Sustained Therapeutic Efficacy of INGREZZA® (valbenazine) 40 mg Capsules
Medium
Report
Neurocrine Biosciences Presents New KINECT® 4 Post-Hoc Analysis Demonstrating Rapid and Sustained Therapeutic Efficacy of INGREZZA® (valbenazine) 40 mg Capsules
10/17
05:44 am
nbix
Neurocrine Biosciences (NASDAQ:NBIX) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
Medium
Report
Neurocrine Biosciences (NASDAQ:NBIX) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
10/9
01:47 pm
nbix
Neurocrine Biosciences (NASDAQ:NBIX) had its price target raised by analysts at UBS Group AG from $188.00 to $195.00. They now have a "buy" rating on the stock.
Low
Report
Neurocrine Biosciences (NASDAQ:NBIX) had its price target raised by analysts at UBS Group AG from $188.00 to $195.00. They now have a "buy" rating on the stock.